Personensuche
Personensuche
Es wurde 1 Person gefunden.
Aktuelle Veranstaltungen
Vergangene Veranstaltungen (max. 10)
Die folgenden Publikationen sind in der Online-Universitätsbibliographie der Universität Duisburg-Essen verzeichnet. Weitere Informationen finden Sie gegebenenfalls auch auf den persönlichen Webseiten der Person.
-
NECTIN4 Amplification Is a Frequent Event in Central Nervous System Metastases of Urothelial CarcinomaIn: European Urology Open Science, Jg. 86, 2026, S. 42 – 46DOI (Open Access)
-
AI-guided virtual biopsy : Automated differentiation of cerebral gliomas from other benign and malignant MRI findings using deep learningIn: Neuro-Oncology Advances, Jg. 7, 2025, Nr. 1, vdae225DOI, Online Volltext (Open Access)
-
Decoding glioblastoma survival : unraveling the prognostic potential of olfactory function in a prospective observational studyIn: Neurological Research and Practice, Jg. 7, 2025, Nr. 1, 51DOI (Open Access)
-
Decoding pan-cancer treatment outcomes using multimodal real-world data and explainable artificial intelligenceIn: Nature Cancer, Jg. 6, 2025, Nr. 2, S. 307 – 322DOI (Open Access)
-
Distribution and prognostic significance of myelotoxicity in newly diagnosed glioblastoma in a real-life cohort : Time to treat more aggressively?In: Neuro-Oncology Advances, Jg. 7, 2025, Nr. 1, vdaf218DOI, Online Volltext (Open Access)
-
In-depth characterization of vaccine-induced neoantigen-specific T cells in patients with IDH1-mutant glioma undergoing personalized peptide vaccinationIn: Journal for ImmunoTherapy of Cancer, Jg. 13, 2025, Nr. 6, e011070DOI (Open Access)
-
Molecularly matched targeted therapies plus radiotherapy in glioblastoma : the phase 1/2a N²M² umbrella trialIn: Nature Medicine, Jg. 31, 2025, Nr. 10, S. 3534 – 3541DOI (Open Access)
-
Quantitative assessment of residual tumor is a strong and independent predictor of survival in methylated glioblastoma following radiochemotherapy with lomustine/temozolomideIn: Neuro-Oncology, Jg. 27, 2025, Nr. 2, S. 557 – 566
-
Temporal Muscle Thickness as a Prognostic Marker in a Real-Life Cohort of Newly Diagnosed MGMT Promoter Methylated Glioblastoma : A Multicentric Imaging AnalysisIn: Cancer Medicine, Jg. 14, 2025, Nr. 8, e70689DOI (Open Access)
-
A real-world observation of patients with glioblastoma treated with a personalized peptide vaccineIn: Nature Communications, Jg. 15, 2024, Nr. 1, 6870DOI (Open Access)
-
Cranioencephalic functional lymphoid units in glioblastomaIn: Nature Medicine, Jg. 30, 2024, Nr. 10, S. 2947 – 2956DOI (Open Access)
-
Global post‑marketing safety surveillance of Tumor Treating Fields (TTFields) therapy in over 25,000 patients with CNS malignancies treated between 2011–2022In: Journal of Neuro-Oncology, Jg. 169, 2024, Nr. 1, S. 25 – 38DOI (Open Access)
-
L-RNA aptamer-based CXCL12 inhibition combined with radiotherapy in newly-diagnosed glioblastoma: dose escalation of the phase I/II GLORIA trialIn: Nature Communications, Jg. 15, 2024, Nr. 1, 4210DOI (Open Access)
-
The Role of Fibroblast Activation Protein in Glioblastoma and Gliosarcoma : A Comparison of Tissue, ⁶⁸Ga-FAPI-46 PET Data, and Survival DataIn: Journal of Nuclear Medicine (JNM), Jg. 65, 2024, Nr. 8, S. 1217 – 1223DOI (Open Access)
-
Prevention and Management of Dermatologic Adverse Events Associated With Tumor Treating Fields in Patients With GlioblastomaIn: Frontiers in Oncology, Jg. 10, 2020, S. 1045DOI (Open Access)
-
18-FET-PET Enhanced Diagnosis of Pseudoprogression in Glioblastome is an Independent Prognostic Fator for Overall SurvivalIn: Neuro-Oncology. Oxford: Oxford University Press, Jg. 26, 2024, Nr. Supplement_5, S. v49 – v50
-
440O First in human study of the mRNA-based cancer vaccine CVGBM in patients (pts) with newly diagnosed and surgically resected MGMT-unmethylated glioblastoma (GBM) : First results from the dose escalation phase
ESMO Congress 2024, 13-17 September 2024, Barcelona, Spain,In: Annals of Oncology. Amsterdam: Elsevier, Jg. 35, 2024, Nr. Suppl. 2, S. S406 -
A CCNU/TMZ in Elderly Patients with MGMT-Methylated Glioblastoma : A Multicentric Retrospective Cohort
19th Meeting of the European Association of Neuro-Oncology (EANO), October 17-20, 2024, Glasgow, UK,In: Neuro-Oncology. Oxford: Oxford University Press, Jg. 26, 2024, Nr. Supplement 5, S. v97 – v97 -
A Tumor Treating Fields (TTFields) Therapy in Patients with Glioblastoma : Long-Term Survival Results from TTFields in Germany in Routine Clinical Care (Tiger) Study
19th Meeting of the European Association of Neuro-Oncology (EANO), October 17-20, 2024, Glasgow, UK,In: Neuro-Oncology. Oxford: Oxford University Press, Jg. 26, 2024, Nr. Supplement 5, S. v143 -
AI Based Prediction of Clinical TTFields Response in Glioblastoma Patients (Retrospective Analysis)
29th Annual Meeting and Education Day of the Society-for-Neuro-Oncology (SNO): NOV 21-24, 2024; Houston, USA,In: Neuro-Oncology. Oxford: Oxford University Press, Jg. 26, 2024, Nr. Suppl. 8: Abstracts from the 2024 Society for Neuro-Oncology’s 29th Annual Meeting and Education Day, S. viii112 – viii112 -
Decoding glioblastoma survival : Unraveling the prognostic potential of olfactory function in a prospective observational study
29th Annual Meeting and Education Day of the Society-for-Neuro-Oncology (SNO): NOV 21-24, 2024; Houston, USA,In: Neuro-Oncology. Oxford: Oxford University Press, Jg. 26, 2024, Nr. Suppl. 8: Abstracts from the 2024 Society for Neuro-Oncology’s 29th Annual Meeting and Education Day, S. viii95 – viii95 -
Dual inhibition of post-radiogenic angio-vasculogenesis in glioblastoma: Results of the phase I/II GLORIA trial
ESMO Congress 2024, 13-17 September 2024, Barcelona, Spain,In: Annals of Oncology. Amsterdam: Elsevier, Jg. 35, 2024, Nr. Suppl. 2, S. S408 -
Final Results from N2M2/NOA-20
29th Annual Meeting and Education Day of the Society-for-Neuro-Oncology (SNO): NOV 21-24, 2024; Houston, USA,In: Neuro-Oncology. Oxford: Oxford University Press, Jg. 26, 2024, Nr. Suppl. 8: Abstracts from the 2024 Society for Neuro-Oncology’s 29th Annual Meeting and Education Day, S. viii117 – viii117 -
First in Human Study of the MRNA-Based Cancer Vaccine CVGBM in Patients (PTS) with Newly-Diagnosed and Surgically Resected MGMT-Unmethylated Glioblastoma (GBM) : First Results from the Dose Escalation Phase
29th Annual Meeting and Education Day of the Society for Neuro-Oncology (SNO), November 21-24, 2024, Houston, TX, USA,In: Neuro-Oncology. Oxford: Oxford University Press, Jg. 26, 2024, Nr. Supplement 8, S. viii86 – viii86 -
N2M2/NOA-20 : Phase I/IIa umbrella trial of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed glioblastoma without MGMT promoter hypermethylationIn: Journal of Clinical Oncology (JCO). Alexandria: American Society of Clinical Oncology (ASCO), Jg. 42, 2024, Nr. Suppl. 16, 2000
-
Phase 1 dose-finding study to evaluate safety and tolerability of CVGBM in patients with newly diagnosed and surgically resected MGMT-unmethylated glioblastomaIn: Journal of Clinical Oncology (JCO). Alexandria: American Society of Clinical Oncology (ASCO), Jg. 42, 2024, Nr. Suppl. 16, TPS2095DOI (Open Access)
-
The Role Of Fibroblast Activation Protein in Glioblastoma and Gliosarcoma : A Comparison Of Tissue, 68ga-Fapi-46 Positron Emission Tomography and Survival Data
29th Annual Meeting and Education Day of the Society for Neuro-Oncology, November 21-24, 2024, Houston, TX, USA,In: Neuro-Oncology. Oxford: Oxford University Press, Jg. 26, 2024, Nr. Supplement 8, S. viii196 – viii197 -
The Role of Fibroblast Activation Protein in Glioblastoma and Gliosarcoma : A Comparison of Tissue, 68GA-FAPI-46 Positron Emission Tomography and Survival Data
19th Meeting of the European Association of Neuro-Oncology (EANO 2024), October 17-20, 2024, Glasgow, UK,In: Neuro-Oncology. Oxford: Oxford University Press, Jg. 26, 2024, Nr. Supplement 5, S. v25 – v25 -
P11.21.A Long-term survival with IDH wildtype glioblastoma : First results from the eternity brain tumor funders’ collaborative consortium (EORTC1419)In: Neuro-Oncology. Oxford: Oxford University Press, Jg. 25, 2023, Nr. Suppl. 2, S. ii77 – ii77DOI, Online Volltext (Open Access)
-
P15.01.A FET PET Sensitivity in primary brain tumors according to CNS who 2021 : Value and pitfalls in presurgical implementationIn: Neuro-Oncology. Oxford: Oxford University Press, Jg. 25, 2023, Nr. Suppl. 2, S. ii109 – ii109DOI, Online Volltext (Open Access)
-
Telemedicine in Neuro-Oncology : An Evaluation of Remote Consultations during the COVID-19 Pandemic
18th Meeting of the European Association of Neuro-Oncology, September 21-24, 2023, Rotterdam, The Netherlands,In: Neuro-Oncology. Oxford: Oxford University Press, Jg. 25, 2023, Nr. Supplement 2, S. ii16 – ii17DOI, Online Volltext (Open Access) -
Target Expression and FAP-Directed Tumour Imaging in a Large, Single-Centre PET Database of 324 Patients and 21 Tumour Entities
EANM‘22 ; 35th Annual Congress of the European Association of Nuclear Medicine ; October 15-19, 2022, Barcelona, Spain,In: European Journal of Nuclear Medicine and Molecular Imaging. Berlin: Springer, Jg. 49, 2022, Nr. Supplement 1, S. S119 – S120DOI (Open Access) -
Frequent overexpression of NECTIN-4 in CNS metastases from urothelial carcinoma
2025 ASCO Genitourinary Cancers Symposium, February 13-15, 2025, San Francisco, CA, USA,In: Journal of Clinical Oncology (JCO). Alexandria: American Society of Clinical Oncology (ASCO), Jg. 43, 2025, Nr. 5, Supplement, 804 -
Tumor treating fields (TTFields) therapy in patients with glioblastoma : Long-term survival results from TTFields in Germany in routine clinical care (TIGER) studyIn: Journal of Clinical Oncology (JCO). Alexandria: American Society of Clinical Oncology (ASCO), Jg. 42, 2024, Nr. 16, 2036DOI (Open Access)